AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21658349 — intervention group
Group type: COMPARATOR
Intervention: 4 KKW exercise (women)
Number of subjects: 126
Study 21658349 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 KKW exercise (men)
Number of subjects: 126
Study 21658349 — intervention group
Group type: COMPARATOR
Intervention: 4 KKW exercise (men)
Number of subjects: 126
Study 19374892 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg single-oral dose) with rifampicin (600 mg single-oral dose)
Number of subjects: 16
Study 19374892 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (40 mg single-oral dose) with placebo
Number of subjects: 16
Study 19374892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (450 mg single-oral dose)
Number of subjects: 16
Study 17088091 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg
Number of subjects: 163
Study 17088091 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 800 microg
Number of subjects: 163
Study 17088091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 17088091 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol (both doses)
Number of subjects: 163
Study 16485735 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CLS2210) given orally for 14 days before the operation (CD group)
Number of subjects: 24
Study 14560084 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspen orthosis
Number of subjects: 12
Study 14560084 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston orthosis
Number of subjects: 12
Study 14560084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cybertech orthosis
Number of subjects: 12
Study 14560084 — intervention group
Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 12
Study 10720272 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryonic porcine VM tissue with cyclosporine immunosuppression
Number of subjects: 12
Study 10720272 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryonic porcine VM tissue treated with a monoclonal antibody directed against major histocompatibility complex class I
Number of subjects: 12
Study 10720272 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 9016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive-load detection thresholds measured by forced oscillation
Number of subjects: 38
Study 9016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking method
Number of subjects: 38
Study 9016469 — intervention group
Group type: EXPERIMENTAL
Intervention: Random method
Number of subjects: 38
Study 9016469 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of adults (n = 10)
Number of subjects: 38
Study 1517950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-fortified formula
Number of subjects: 20
Study 1517950 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan-unfortified formula
Number of subjects: 20
Study 1517950 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed
Number of subjects: 20
Study 6829517 — intervention group
Group type: EXPERIMENTAL
Intervention: Paregoric
Number of subjects: 153
Study 6829517 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 153
Study 6829517 — intervention group
Group type: COMPARATOR
Intervention: No specific pharmacotherapy
Number of subjects: 153
Study 29666180 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (ET)
Number of subjects: 108
Study 29666180 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 108
Study 29183074 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT by oral capsule
Number of subjects: 116
Study 25316182 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional walking, endurance, balance, and strength (WEBS) intervention (n=20)
Number of subjects: 44
Study 25316182 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing and coordination of gait (TC) intervention (n=22)
Number of subjects: 44
Study 23297781 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual peer support
Number of subjects: 165
Study 23297781 — intervention group
Group type: EXPERIMENTAL
Intervention: Group peer support
Number of subjects: 165
Study 23297781 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined peer support (individual and group)
Number of subjects: 165
Study 23297781 — intervention group
Group type: COMPARATOR
Intervention: No peer support (control)
Number of subjects: 165
Study 21719165 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard glucose infusion (SG; 5.0 mg kg(‐1) min(‐1))
Number of subjects: 8
Study 21719165 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glucose infusion (LG; 2.5 mg kg(‐1) min(‐1))
Number of subjects: 8
Study 18329563 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (30 mg)
Number of subjects: 10
Study 18329563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16401810 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine 200 mg once daily for 48 weeks
Number of subjects: 248
Study 16401810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 15536785 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally delivered minocycline microspheres (Arestin) as an adjunct to scaling and root planing (SRP)
Number of subjects: 20
Study 15536785 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 20
Study 11428837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol therapy
Number of subjects: 0
Study 11428837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9284986 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of low doses of allergen
Number of subjects: 9
Study 9284986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inhalation of PHA alone)
Number of subjects: 9
Study 9284986 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (allergen and placebo)
Number of subjects: 9
Study 8328415 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (surface cooling)
Number of subjects: 29
Study 8328415 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (surface warming and insulation)
Number of subjects: 29
Study 3521401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethaverine 200 mg four times daily
Number of subjects: 45
Study 3521401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31096265 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 17
Study 31096265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29686481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 30
Study 29686481 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 30
Study 27183112 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic complete mesocolic excision (CME)
Number of subjects: 0
Study 27183112 — intervention group
Group type: COMPARATOR
Intervention: D3 lymphadenectomy
Number of subjects: 0
Study 24183827 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training
Number of subjects: 46
Study 24183827 — intervention group
Group type: COMPARATOR
Intervention: Live volunteer training
Number of subjects: 46
Study 23760155 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response syndrome at presentation
Number of subjects: 1903
Study 23760155 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response syndrome at 24 hours
Number of subjects: 1903
Study 23760155 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional systemic inflammatory response syndrome criterion at presentation
Number of subjects: 1903
Study 23760155 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional systemic inflammatory response syndrome criterion at 24 hours
Number of subjects: 1903
Study 23760155 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality at 90 days
Number of subjects: 1903
Study 20568386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg subcutaneous)
Number of subjects: 96
Study 20568386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 17534380 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg nicotine
Number of subjects: 10
Study 17534380 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg nicotine
Number of subjects: 10
Study 17534380 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg nicotine
Number of subjects: 10
Study 17534380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17534380 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg and 0.7 mg nicotine
Number of subjects: 10
Study 16912129 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (5 microg ethinyl estradiol and 1 mg norethindrone acetate)
Number of subjects: 10
Study 16912129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12654170 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.6 g n‐3 PUFA/d
Number of subjects: 60
Study 12654170 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g n‐3 PUFA/d
Number of subjects: 60
Study 12654170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 60
Study 10799791 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity
Number of subjects: 129
Study 10799791 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior physical functioning
Number of subjects: 129
Study 10799791 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient age
Number of subjects: 129
Study 10799791 — intervention group
Group type: EXPERIMENTAL
Intervention: Current symptomatology
Number of subjects: 129
Study 8797007 — intervention group
Group type: EXPERIMENTAL
Intervention: Method to distinguish between susceptibility locus and necessary locus using linkage analysis and marker loci.
Number of subjects: 0
Study 1495569 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1800 mg EPA and 1200 mg DHA)
Number of subjects: 17
Study 1495569 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (3000 mg omega-6 linoleic acid)
Number of subjects: 17
Study 6089305 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine twice daily
Number of subjects: 58
Study 6089305 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine three times daily and 400 mg at night
Number of subjects: 58
Study 6089305 — intervention group
Group type: COMPARATOR
Intervention: Placebo matching ranitidine twice daily
Number of subjects: 58
Study 6089305 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine at night
Number of subjects: 58
Study 6089305 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 58
Study 30334082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 30334082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle
Number of subjects: 3234
Study 30334082 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3234
Study 30022618 — intervention group
Group type: EXPERIMENTAL
Intervention: Baerveldt glaucoma drainage device (BGI)
Number of subjects: 119
Study 30022618 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy (TE)
Number of subjects: 119
Study 27098500 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-knot technique (SKT)
Number of subjects: 260
Study 27098500 — intervention group
Group type: COMPARATOR
Intervention: Multiple-knot technique (MKT)
Number of subjects: 260
Study 24884787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment (n=16)
Number of subjects: 26
Study 24884787 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control, n=10)
Number of subjects: 26
Study 22261813 — intervention group
Group type: EXPERIMENTAL
Intervention: Active robot‐assisted intervention (FTI group, 20 sessions over 4 weeks)
Number of subjects: 17
Study 22261813 — intervention group
Group type: COMPARATOR
Intervention: Early passive therapy followed by active robot‐assisted intervention (HTI group, 10 sessions of passive therapy followed by 10 sessions of active therapy)
Number of subjects: 17
Study 19748619 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich oil (ERO, 3.3g EPA/day)
Number of subjects: 38
Study 19748619 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil (DRO, 3.7g DHA/day)
Number of subjects: 38
Study 19748619 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil (DRO)
Number of subjects: 38
Study 19748619 — intervention group
Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 38
Study 17178187 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 32
Study 17178187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 32
Study 15929759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype pediatric colonoscope with short bending in four directions (PCF-AYL)
Number of subjects: 174
Study 15929759 — intervention group
Group type: COMPARATOR
Intervention: Standard pediatric colonoscope (Olympus PCF‐160)
Number of subjects: 174
Study 15929759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype pediatric colonoscope with short bending in two directions (PCF-AY3L)
Number of subjects: 174
Study 15929759 — intervention group
Group type: COMPARATOR
Intervention: Prototype 170 degrees wide angle colonoscope with standard bending section length (CFQ160-WL)
Number of subjects: 174
Study 15929759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype 170 degrees colonoscope with a short bending section (CFQ160-W2L)
Number of subjects: 174
Study 12766103 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine administered before breakfast
Number of subjects: 378
Study 12766103 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine administered before dinner
Number of subjects: 378
Study 12766103 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine administered at bedtime
Number of subjects: 378
Study 10851101 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (4-week program focusing on strength and endurance of back and abdominal muscles)
Number of subjects: 20
Study 10851101 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal postoperative care with physiotherapist advice)
Number of subjects: 20
Study 8671131 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy at 800 Hz
Number of subjects: 19
Study 8671131 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy or treatment with 600 Hz
Number of subjects: 19
Study 8671131 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy
Number of subjects: 19
Study 1582116 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg)
Number of subjects: 261
Study 1582116 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg)
Number of subjects: 261
Study 3907792 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg fentanyl followed by thiopentone
Number of subjects: 28
Study 3907792 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone alone
Number of subjects: 28
Study 29745007 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0113 (5 mg, 5 doses on Days 30/60/90/120/180 posttransplant)
Number of subjects: 149
Study 29745007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 29745007 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0113
Number of subjects: 149
Study 27349747 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + Letrozole
Number of subjects: 165
Study 27349747 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 165
Study 24718775 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg oral melatonin
Number of subjects: 95
Study 24718775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 23302558 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum and Bifidobacterium combined Powder (5×10^9 CFU daily for 7 days)
Number of subjects: 372
Study 23302558 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine antibiotics treatment)
Number of subjects: 372
Study 20395115 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 18
Study 20395115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17644419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (three-component treatment: relaxation training, stimulus control, sleep hygiene instructions)
Number of subjects: 0
Study 17644419 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study 16010198 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile sensory threshold greater than 0.5 g
Number of subjects: 80
Study 16010198 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminability less than 0.50
Number of subjects: 80
Study 16010198 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-choice scores less than 90%
Number of subjects: 80
Study 16010198 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-chance scores
Number of subjects: 80
Study 16010198 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores beyond cut-offs
Number of subjects: 80
Study 14714120 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine daily
Number of subjects: 95
Study 14714120 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg fluoxetine daily
Number of subjects: 95
Study 14714120 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine once every third day
Number of subjects: 95
Study 12172973 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptaplatin 400 mg/m(2) i.v. over 1 h on day 1 plus 5‐fluorouracil (5‐FU) 1000 mg/m(2) per day continuous i.v. from day 1 to day 5
Number of subjects: 99
Study 12172973 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 60 mg/m(2) i.v. over 1 h on day 1 plus 5‐fluorouracil (5‐FU) 1000 mg/m(2) per day continuous i.v. from day 1 to day 5
Number of subjects: 99
Study 9708751 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus acetazolamide (100 mg/kg daily) and furosemide (1 mg/kg daily)
Number of subjects: 177
Study 9708751 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 177
Study 9708751 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus acetazolamide and furosemide
Number of subjects: 177
Study 7608727 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition A (baseline thermode temperature at 30 degrees C)
Number of subjects: 20
Study 7608727 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition B (baseline thermode temperature at 35 degrees C)
Number of subjects: 20
Study 7608727 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition C (baseline thermode temperature at 35 degrees C and warmed skin area to 35 degrees C)
Number of subjects: 20
Study 7608727 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference limen (DL) thresholds
Number of subjects: 20
Study 7608727 — intervention group
Group type: EXPERIMENTAL
Intervention: General recommendation
Number of subjects: 20
Study 2196030 — intervention group
Group type: EXPERIMENTAL
Intervention: Curosurf (200 mg/kg) given intratracheally
Number of subjects: 30
Study 2196030 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Curosurf)
Number of subjects: 30
Study 117496 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Gain Condition
Number of subjects: 40
Study 117496 — intervention group
Group type: COMPARATOR
Intervention: Incentive Loss Condition
Number of subjects: 40
Study 6315123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone 100 mg daily
Number of subjects: 0
Study 6315123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone 200 mg daily
Number of subjects: 0
Study 6315123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone 300 mg daily
Number of subjects: 0
Study 6315123 — intervention group
Group type: COMPARATOR
Intervention: Conjugated oestrogens 1.25 mg daily
Number of subjects: 0
Study 30558672 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous spacer injection (4-10 cc of biodegradable hyaluronic acid)
Number of subjects: 230
Study 30558672 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spacer injection)
Number of subjects: 230
Study 30558672 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous spacer injection
Number of subjects: 230
Study 26940095 — intervention group
Group type: COMPARATOR
Intervention: GSTM1 active/APOL1 low‐risk (reference group)
Number of subjects: 682
Study 26940095 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 active/APOL1 high‐risk
Number of subjects: 682
Study 26940095 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 null/APOL1 low‐risk
Number of subjects: 682
Study 26940095 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 null/APOL1 high‐risk
Number of subjects: 682
Study 25161019 — intervention group
Group type: COMPARATOR
Intervention: Standard polyurethane (SPU) dressing (control)
Number of subjects: 195
Study 25161019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bordered polyurethane (BPU) + SPU dressing
Number of subjects: 195
Study 25161019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive (TA) + SPU dressing
Number of subjects: 195
Study 25161019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless securement device (SSD) + SPU dressing
Number of subjects: 195
Study 25161019 — intervention group
Group type: COMPARATOR
Intervention: All groups compared to control (SPU)
Number of subjects: 195
Study 22123332 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with additional excitatory stimuli
Number of subjects: 59
Study 22123332 — intervention group
Group type: COMPARATOR
Intervention: Exposure without additional excitatory stimuli
Number of subjects: 59
Study 22123332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained arousal throughout exposure
Number of subjects: 59
Study 22123332 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in subjective fear responding during exposure
Number of subjects: 59
Study 19513794 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heating (Group 1)
Number of subjects: 22